Kodiak Sciences (KOD) Shares Outstanding (Diluted Average) (2020 - 2026)
Kodiak Sciences (KOD) reported Shares Outstanding (Diluted Average) of $61.9 million for Q1 2026, up 17.28% on a YoY basis from $52.7 million in Q1 2025, and up 16.26% quarter-over-quarter from $53.2 million in Q4 2025.
Kodiak Sciences (KOD) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Kodiak Sciences has reported Shares Outstanding (Diluted Average) for 7 years, with the latest figure at $61.9 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 17.28% year-over-year to $61.9 million; the trailing twelve-month figure through Mar 2026 stood at $61.9 million (up 17.28% YoY), and the FY2025 full-year result was $53.2 million, up 1.19% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $61.9 million, up from $53.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $61.9 million in Q1 2026, with the low at $52.2 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $53.1 million across 5 years, with a median of $52.5 million in 2024.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) advanced 0.2% — and 2026, when it rose 17.28%.
- Kodiak Sciences' Shares Outstanding (Diluted Average) stood at $52.2 million in 2022, then grew by 0.32% to $52.4 million in 2023, then gained by 0.32% to $52.6 million in 2024, then increased by 1.19% to $53.2 million in 2025, then grew by 16.26% to $61.9 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $61.9 million (Q1 2026), $53.2 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 92.44 Mn |
| 10 | Kodiak Sciences | 1.92 Bn | 1.92 Bn | - | 61.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.86 Mn |
| Dec 31, 2025 | 53.21 Mn |
| Sep 30, 2025 | 52.80 Mn |
| Jun 30, 2025 | 52.78 Mn |
| Mar 31, 2025 | 52.75 Mn |
| Dec 31, 2024 | 52.58 Mn |
| Sep 30, 2024 | 52.56 Mn |
| Jun 30, 2024 | 52.53 Mn |
| Mar 31, 2024 | 52.51 Mn |
| Dec 31, 2023 | 52.41 Mn |
| Sep 30, 2023 | 52.46 Mn |
| Jun 30, 2023 | 52.36 Mn |
| Mar 31, 2023 | 52.34 Mn |
| Dec 31, 2022 | 52.25 Mn |
| Sep 30, 2022 | 52.23 Mn |
| Jun 30, 2022 | 52.22 Mn |
| Mar 31, 2022 | 52.17 Mn |
| Dec 31, 2021 | 51.79 Mn |
| Sep 30, 2021 | 51.72 Mn |
| Jun 30, 2021 | 51.64 Mn |